Legal status in the United States
Peptide legal status: FDA, DEA and WADA, compound by compound
Read at FDA, DEA and WADAPublished by PepVault
Of the 93 compounds below, 21 have an FDA-approved product and 72 have none (14 of those are in company trials); none is a federally controlled substance, and WADA bans 24 of them in sport.
How many are approved

Every compound, read Nov 18, 2026
FDA-approved
An FDA-approved drug holds this active ingredient (where Drugs@FDA lists every product as discontinued, the row says so).
| Compound | FDA approval | Compounding | DEA schedule | Sport (WADA) |
|---|---|---|---|---|
| Semaglutide | Approved (Ozempic, 2017) | Approved drug; not in shortage | Not controlled | Not named on the list |
| Tirzepatide | Approved (Mounjaro, 2022) | Approved drug; not in shortage | Not controlled | Not named on the list |
| Liraglutide | Approved (Victoza, 2010) | Approved drug; FDA proposes no 503B listing | Not controlled | Not named on the list |
| Tesamorelin | Approved (Egrifta, 2010) | A biologic; FDA: not eligible for 503A or 503B | Not controlled | Banned, named (S2.2.4) |
| HGH | Approved (Humatrope, 1986) | A biologic; FDA: not eligible for 503A or 503B | Not controlled; own statute (21 U.S.C. 333(e)) | Banned, named (S2.2.3) |
| PT-141 | Approved (Vyleesi, 2019) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Sermorelin | Approved 1990; discontinued (Drugs@FDA) | Component of an approved drug (503A condition) | Not controlled | Banned, named (S2.2.4) |
| Semaglutide (oral) | Approved (Rybelsus, 2019) | Approved drug; not in shortage | Not controlled | Not named on the list |
| Dulaglutide | Approved (Trulicity, 2014) | A biologic; FDA: not eligible for 503A or 503B | Not controlled | Not named on the list |
| Orforglipron | Approved (Foundayo, 2026) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Melanotan I | Approved (Scenesse, 2019) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Exenatide | Approved (Byetta, 2005) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Setmelanotide | Approved (Imcivree, 2020) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Teriparatide | Approved (Forteo, 2002) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Abaloparatide | Approved (Tymlos, 2017) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Pramlintide | Approved 2005; discontinued (Drugs@FDA) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Linaclotide | Approved (Linzess, 2012) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| SS-31 | Approved (Forzinity, 2025) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| Oxytocin | Approved (Syntocinon, 1980) | Component of an approved drug (503A condition) | Not controlled | Not named on the list |
| HCG | Approved (Chorionic Gonadotropin, 1973) | A biologic; FDA: not eligible for 503A or 503B | Not controlled | Banned for males, named (S2.2.1) |
| Clomiphene | Approved (Clomid, 1967) | Component of an approved drug (503A condition) | Not controlled | Banned, named (S4.2) |
- FDA approval
- Approved (Ozempic, 2017)
- Compounding
- Approved drug; not in shortage
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Mounjaro, 2022)
- Compounding
- Approved drug; not in shortage
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Victoza, 2010)
- Compounding
- Approved drug; FDA proposes no 503B listing
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Egrifta, 2010)
- Compounding
- A biologic; FDA: not eligible for 503A or 503B
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.4)
- FDA approval
- Approved (Humatrope, 1986)
- Compounding
- A biologic; FDA: not eligible for 503A or 503B
- DEA
- Not controlled; own statute (21 U.S.C. 333(e))
- Sport
- Banned, named (S2.2.3)
- FDA approval
- Approved (Vyleesi, 2019)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved 1990; discontinued (Drugs@FDA)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.4)
- FDA approval
- Approved (Rybelsus, 2019)
- Compounding
- Approved drug; not in shortage
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Trulicity, 2014)
- Compounding
- A biologic; FDA: not eligible for 503A or 503B
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Foundayo, 2026)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Scenesse, 2019)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Byetta, 2005)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Imcivree, 2020)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Forteo, 2002)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Tymlos, 2017)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved 2005; discontinued (Drugs@FDA)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Linzess, 2012)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Forzinity, 2025)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Syntocinon, 1980)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Approved (Chorionic Gonadotropin, 1973)
- Compounding
- A biologic; FDA: not eligible for 503A or 503B
- DEA
- Not controlled
- Sport
- Banned for males, named (S2.2.1)
- FDA approval
- Approved (Clomid, 1967)
- Compounding
- Component of an approved drug (503A condition)
- DEA
- Not controlled
- Sport
- Banned, named (S4.2)
In clinical trials, not approved
No FDA-approved product; a company trial is listed on ClinicalTrials.gov (each page links it).
| Compound | FDA approval | Compounding | DEA schedule | Sport (WADA) |
|---|---|---|---|---|
| Retatrutide | Not approved; in phase 3 trials | Barred from compounding (FDA) | Not controlled | Not named; from 2027, S0 names peptides in general |
| MK-677 | Not approved; in a phase 3 trial | On FDA’s safety-risk list (category 2) | Not controlled | Banned, named (S2.2.4) |
| Thymosin Beta-4 | Not approved; in a phase 2 trial | Not named on FDA’s lists | Not controlled | Banned, named (S2.3) |
| Cagrilintide | Not approved; in phase 3 trials | Barred from compounding (FDA) | Not controlled | Not named; from 2027, S0 names peptides in general |
| CagriSema | Not approved; in phase 3 trials | Barred from compounding (FDA) | Not controlled | Not named; from 2027, S0 names peptides in general |
| Survodutide | Not approved; in phase 3 trials | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Pemvidutide | Not approved; in a phase 3 trial | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Eloralintide | Not approved; in phase 3 trials | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Petrelintide | Not approved; in phase 3 trials | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Amycretin | Not approved; in phase 3 trials | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| VK2735 | Not approved; in phase 3 trials | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Enicepatide | Not approved; in phase 3 trials | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Ecnoglutide | Not approved; in phase 3 trials | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Larazotide | Not approved; in a phase 3 trial | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Barred from compounding (FDA)
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in a phase 3 trial
- Compounding
- On FDA’s safety-risk list (category 2)
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.4)
- FDA approval
- Not approved; in a phase 2 trial
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Banned, named (S2.3)
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Barred from compounding (FDA)
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Barred from compounding (FDA)
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in a phase 3 trial
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in phase 3 trials
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved; in a phase 3 trial
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
Not approved
No FDA-approved product.
| Compound | FDA approval | Compounding | DEA schedule | Sport (WADA) |
|---|---|---|---|---|
| BPC-157 | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Banned, named (S0) |
| TB-500 | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Banned, named (S2.3) |
| GHK-Cu | Not approved | Under FDA evaluation, not for injection (503A category 1) | Not controlled | Not named; from 2027, S0 names peptides in general |
| Melanotan II | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named; from 2027, S0 names peptides in general |
| CJC-1295 with DAC | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Banned, named (S2.2.4) |
| CJC-1295 no DAC | Not approved | Not checked yet | Not controlled | Banned by its class (S2.2.4) |
| Ipamorelin | Not approved | On FDA’s safety-risk list for outsourcing facilities (503B category 2) | Not controlled | Banned, named (S2.2.4) |
| AOD-9604 | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Banned, named (S2.2.3) |
| Semax | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named; from 2027, S0 names peptides in general |
| NAD+ | Not approved | Under FDA evaluation (503A category 1) | Not controlled | Not named on the list |
| MOTS-c | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Banned, named (S4.4.1) |
| KPV | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named; from 2027, S0 names peptides in general |
| Epitalon | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named; from 2027, S0 names peptides in general |
| DSIP | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named; from 2027, S0 names peptides in general |
| Selank | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named; from 2027, S0 names peptides in general |
| Thymosin Alpha-1 | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named; from 2027, S0 names peptides in general |
| LL-37 | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named; from 2027, S0 names peptides in general |
| Dihexa | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Not named on the list |
| PEG-MGF | Not approved | Nomination withdrawn; on no FDA list | Not controlled | Banned by its class (S2.3) |
| IGF-1 LR3 | Not approved | Not named on FDA’s lists | Not controlled | Banned by its class (S2.3) |
| Kisspeptin-10 | Not approved | On FDA’s safety-risk list (category 2) | Not controlled | Banned for males, by its class (S2.2.1) |
| GHRP-2 | Not approved | Safety-risk list for outsourcing facilities (503B category 2) | Not controlled | Banned, named (S2.2.4) |
| GHRP-6 | Not approved | Safety-risk list for outsourcing facilities (503B category 2) | Not controlled | Banned, named (S2.2.4) |
| Hexarelin | Not approved | Not named on FDA’s lists | Not controlled | Banned, named (S2.2.4) |
| VIP | Not approved | Under FDA evaluation (503A category 1) | Not controlled | Not named; from 2027, S0 names peptides in general |
| Mazdutide | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Efinopegdutide | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Thymalin | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Thymogen | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Vilon | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Cartalax | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Pinealon | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Vesugen | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Livagen | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Bronchogen | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Pancragen | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Cardiogen | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Prostamax | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Ovagen | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Cortagen | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Humanin | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| FOXO4-DRI | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| SNAP-8 | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| P21 | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Cerebrolysin | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| N-Acetyl Semax Amidate | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Adamax | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Ac-SDKP | Not approved | Not named on FDA’s lists | Not controlled | Not named; from 2027, S0 names peptides in general |
| Klotho | Not approved | Not named on FDA’s lists | Not controlled | Not named on the list |
| NMN | Not approved | Not named on FDA’s lists | Not controlled | Not named on the list |
| 5-Amino-1MQ | Not approved | Not named on FDA’s lists | Not controlled | Not named on the list |
| NSI-189 | Not approved | Not named on FDA’s lists | Not controlled | Not named on the list |
| Fragment 176-191 | Not approved | Not named on FDA’s lists | Not controlled | Banned, named (S2.2.3) |
| Follistatin-344 | Not approved | Not named on FDA’s lists | Not controlled | Banned, named (S4.3) |
| ARA-290 | Not approved | Nominated without adequate support (503A category 3) | Not controlled | Banned by its class (S2.1.5) |
| Enclomiphene | Not approved | Under FDA evaluation (503A category 1) | Not controlled | Banned by its class (S4.2) |
| Glutathione | No drug of its own; an ingredient of an eye-surgery rinse | Under FDA evaluation (503A category 1) | Not controlled | Not named on the list |
| SLU-PP-332 | Not approved | Not named on FDA’s lists | Not controlled | Not named in 2026; named from January 1, 2027 (S4.4.1) |
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Banned, named (S0)
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Banned, named (S2.3)
- FDA approval
- Not approved
- Compounding
- Under FDA evaluation, not for injection (503A category 1)
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.4)
- FDA approval
- Not approved
- Compounding
- Not checked yet
- DEA
- Not controlled
- Sport
- Banned by its class (S2.2.4)
- FDA approval
- Not approved
- Compounding
- On FDA’s safety-risk list for outsourcing facilities (503B category 2)
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.4)
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.3)
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Under FDA evaluation (503A category 1)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Banned, named (S4.4.1)
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Not approved
- Compounding
- Nomination withdrawn; on no FDA list
- DEA
- Not controlled
- Sport
- Banned by its class (S2.3)
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Banned by its class (S2.3)
- FDA approval
- Not approved
- Compounding
- On FDA’s safety-risk list (category 2)
- DEA
- Not controlled
- Sport
- Banned for males, by its class (S2.2.1)
- FDA approval
- Not approved
- Compounding
- Safety-risk list for outsourcing facilities (503B category 2)
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.4)
- FDA approval
- Not approved
- Compounding
- Safety-risk list for outsourcing facilities (503B category 2)
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.4)
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.4)
- FDA approval
- Not approved
- Compounding
- Under FDA evaluation (503A category 1)
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named; from 2027, S0 names peptides in general
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Banned, named (S2.2.3)
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Banned, named (S4.3)
- FDA approval
- Not approved
- Compounding
- Nominated without adequate support (503A category 3)
- DEA
- Not controlled
- Sport
- Banned by its class (S2.1.5)
- FDA approval
- Not approved
- Compounding
- Under FDA evaluation (503A category 1)
- DEA
- Not controlled
- Sport
- Banned by its class (S4.2)
- FDA approval
- No drug of its own; an ingredient of an eye-surgery rinse
- Compounding
- Under FDA evaluation (503A category 1)
- DEA
- Not controlled
- Sport
- Not named on the list
- FDA approval
- Not approved
- Compounding
- Not named on FDA’s lists
- DEA
- Not controlled
- Sport
- Not named in 2026; named from January 1, 2027 (S4.4.1)
What each column means
FDA approval
Whether an FDA-approved drug holds the compound as its active ingredient, read on Drugs@FDA and in the drug’s label on DailyMed, with the year of the first approval. Where none is approved, a company trial listed on ClinicalTrials.gov is named with its phase.
Compounding
What FDA’s compounding lists say. Pharmacies (section 503A) may compound from a bulk substance without a USP monograph or an approved drug only once it is on the 503A bulks list; FDA sorts nominated substances into category 1 (under evaluation), category 2 (may raise significant safety risks) and category 3 (nominated without adequate support). Outsourcing facilities (503B) need the 503B bulks list or a drug in shortage.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
DEA schedule
Whether the compound is a federally controlled substance: searched by name in the schedules (21 CFR Part 1308) and on the DEA’s alphabetical list of controlled substances. One compound here has a statute of its own: human growth hormone is not a controlled substance, but 21 U.S.C. 333(e) makes it a crime to distribute it, or possess it with intent to distribute, for uses FDA hasn’t authorized.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
- 21 U.S.C. 333, Penalties (United States Code, 2024 edition), U.S. Government Publishing Office (govinfo). Read .
Sport (WADA)
Whether the World Anti-Doping Agency’s Prohibited List in force today names the compound, or covers it by a class such as S2 (peptide hormones, growth factors, related substances and mimetics). Every class it names here is banned at all times, in and out of competition. WADA’s 2027 list comes into effect on January 1, 2027; it adds “peptides” to S0’s examples of non-approved substances and names SLU-PP-332 under S4.4.1, and each page whose row it changes gives both lists’ facts.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
- World Anti-Doping Code International Standard, Prohibited List 2027 (comes into effect on January 1, 2027), World Anti-Doping Agency. Read .
What this means and doesn’t
The table reports what the agencies’ own pages said in the United States when we read them on November 18, 2026; each compound’s page links every source. It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ.